Humanigen's lenzilumab shows rapid improvement in oxygenation, discharge

• Humanigen (NASDAQ:HGEN) announces patient case report on the use of lenzilumab in critical COVID-19.
• The published case describes a 77-year-old patient with a past medical history of type II diabetes and heart disorder. The patient tested positive for COVID-19 and was admitted to the ICU in March 2020.
• The patient was treated with steroids, broad spectrum antibiotics for community acquired pneumonia and bronchodilators for possible COPD exacerbation and hydroxychloroquine with zinc.
• The patient continued to deteriorate for the next 12 weeks with an increase in oxygen demand and eventually intermittent bilevel positive airway pressure and developed acute respiratory distress syndrome during that time.
• At week 13, seven days following the administration of lenzilumab, the patient's oxygen decreased from high-flow to low-flow nasal cannula and the patient was discharged from the hospital on home oxygen.
• https://seekingalpha.com/news/3619382-humanigens-lenzilumab-shows-rapid-improvement-in-oxygenation-and-discharge